{
    "2018-07-04": [
        [
            {
                "time": "2018-01-02",
                "original_text": "The Performance of Novo Nordisk’s Premix and Fast-Acting Insulin",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "Premix",
                        "Fast-Acting",
                        "Insulin"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "NVO’s Tresiba and Xultophy Could See Solid Growth in 2018",
                "features": {
                    "keywords": [
                        "NVO",
                        "Tresiba",
                        "Xultophy",
                        "Solid Growth"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Oral Semaglutide Could Be Novo Nordisk’s Long-Term Growth Driver",
                "features": {
                    "keywords": [
                        "Oral Semaglutide",
                        "Novo Nordisk",
                        "Long-Term",
                        "Growth Driver"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}